Patients at intermediate risk of cancer include men with polymyositis, immune-mediated necrotizing myopathy (IMNM), clinically amyopathic dermatomyositis (CADM), and anti-small ubiquitin-like modifier-1 activating enzyme (anti-SAE1), anti-3-hydroxy-3-methylglutaryl coA reductase (anti-HMGCR), anti-Mi2, and anti-MDA5 antibodies. Here, HMGCR is linked to clinically amyopathic dermatomyositis.